Acorda Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is a biopharmaceutical company that develops and commercializes therapies to restore neurological function and improve the lives of people living with neurological disorders, including Parkinson's disease, multiple sclerosis, and spinal cord injury. The company, founded in 1995 and headquartered in Pearl River, New York, previously manufactured and marketed Ampyra (dalfampridine), an extended-release tablet approved by the FDA to improve walking in adults with multiple sclerosis; Inbrija (levodopa inhalation powder), an inhaled prescription medicine indicated as an adjunct to carbidopa/levodopa for the intermittent treatment of OFF episodes in Parkinson's disease patients; and Zanaflex capsules (tizanidine), a short-acting muscle relaxant for spasticity management. It also advanced a pipeline that included BTT1023 (timolumab) in phase II for primary sclerosing cholangitis; CVT-427 (zolmitriptan) in phase I for acute migraine treatment; and rHIgM22, a remyelinating antibody in phase I for multiple sclerosis, alongside proprietary ARCUS technology for pulmonary drug delivery. In April 2024, Acorda filed for Chapter 11 bankruptcy protection amid financial challenges, leading to a court-structured 363 sale of its key assets. On July 10, 2024, Merz Therapeutics completed a $185 million asset purchase agreement acquiring INBRIJA, AMPYRA (dalfampridine, marketed as FAMPYRA outside the U.S.), and related assets including ARCUS technology, with these products continuing to be available to customers through Merz. As of August 21, 2024, Acorda exited bankruptcy, and all remaining assets transferred to the Acorda Therapeutics Liquidation Trust, resulting in the company's delisting from Nasdaq. Previously, in January 2021, Acorda sold its Inbrija manufacturing operations to Catalent for $70 million to cut costs, and in January 2024, it regained global commercialization rights to FAMPYRA from Biogen effective January 2025. The company historically operated primarily in the United States and select international markets through partnerships, targeting neurologists and patients with central nervous system disorders.
Acorda Therapeutics Announces Delisting from Nasdaq
Acorda Therapeutics Announces Nasdaq Delisting Notification
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
Tom Burns Elected to the Acorda Therapeutics Board of Directors
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
Acorda Therapeutics Reports First Quarter 2023 Financial Results
Acorda Therapeutics Reports First Quarter 2023 Financial Results
3 Penny Stocks to Avoid as Interest Rates Rise in 2023